Bli medlem
Bli medlem

Du är här


VEXIM SA: VEXIM announces its participation in the Smallcap Event on April 27 and 28 in Paris

Innovative back microsurgery

Press release

VEXIM announces its participation in the Smallcap Event

on April 27 and 28 in Paris

Toulouse, April 20, 2015
-VEXIM (FR0011072602 - ALVXM / PEA-PME eligible)
, a medical device company specializing in the minimally invasive treatment of
vertebral fractures, announces today that it will participate in the Smallcap
Event, a forum dedicated to meetings between institutional investors and
listed companies from Euronext Paris. The Smallcap Event will take place on
April 27 and 28 in Paris at the "Paris Pullman Tour Eiffel".

During these two days, Vincent Gardès, CEO, and José Da Gloria, Chief
Financial Officer, will meet with institutional investors to present VEXIM's
development strategy, as well as the significant advances that were recently

Next Communication:

First Half 2015 Sales results: July 20th2015*

First Half 2015 Financial results: September 30th 2015*
*indicative dates

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company
created in February 2006. The Company has specialized in the creation and
marketing of minimally-invasive solutions for treating traumatic spinal
pathologies. Benefitting from the financial support of it longstanding
shareholder, Truffle Capital[1]and from OSEO public subsidies, Vexim has
designed and developed the SpineJack®, a unique implant capable of repairing
a fractured vertebra and restoring the balance of the spinal column. The
Company currently has 60 members on its staff. It has its own sales teams in
France, Germany, Italy, Spain, Switzerland, the United Kingdom and United
States, as well as distributors in Turkey, Argentina, Taiwan, Belgium,
Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama,
Venezuela, Chile, Peru and Ecuador and in the following countries where the
product is currently being registered: Mexico, Brazil. Vexim has been listed
on NYSE Alternext Paris since May 2012. For further information, please

SpineJack®, a revolutionary implant for treating Vertebral Compression

The revolutionary aspect of the SpineJack® lies in its ability to restore a
fractured vertebra to its original shape, restore the spinal column's optimal
anatomy and thus remove pain and enable the patient to recover their
functional capabilities. Thanks to a specialized range of instruments,
inserting the implants into the vertebra is carried out by minimally-invasive
surgery, guided by X-ray, in approximately 30 minutes, enabling the patient
to be discharged shortly after surgery. The SpineJack® range consists of 3
titanium implants with 3 different diameters, thus covering 95% of vertebral
compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific
experts in the field of spine surgery and worldwide patent protection through
to 2029.


| VEXIM Alize RP LifeSci Advisors LLC |
| |
|Vincent Gardès Relations presse Investor Relations |
| Caroline Carmagnol Michael Wood |
|CEO |
| |
| |
| Tél : 01 44 54 36 66 / 06 64 18 99 59 +1 646 597 6983 |
| |
|Tel: +33 5 61 48 48 38 |
| * Name: VEXIM |
| * ISIN code: FR0011072602 |
| * Ticker: ALVXM |

---------------------------------------[1]Founded in 2001 in Paris, Truffle Capital is a leading independent European
private equity firm. It is dedicated to investing in and building technology
leaders in the IT, life sciences and energy sectors. Truffle Capital manages
€550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked
during 7 to 10 years). For further information, please

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VEXIM SA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.